Timing of intratracheal administration of budesonide mixed with surfactant to prevent bronchopulmonary dysplasia: a systematic review and meta-analysis.

Eur J PediatrOct 29, 2026 (epub)
Clinical ResearchPediatricsPulmonologyOpen access

Yohei Minamitani, Kana Saito, Naoyuki Miyahara et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined randomised trials comparing intratracheal budesonide mixed with surfactant against surfactant alone in infants, assessing bronchopulmonary dysplasia (BPD) and whether treatment timing explained differences between trials. Across 14 trials reporting BPD at 36 weeks’ postmenstrual age (BPD36), the overall estimate suggested lower risk with combination therapy (RR 0.71; 95% CI, 0.59-0.86), with substantial heterogeneity. In a post hoc subgroup analysis, benefit was seen in trials restricting treatment to within 4 h after birth, but not in trials permitting later treatment. The authors consider this finding hypothesis-generating and do not support routine use.

Key findings

  • Overall, BPD36 was lower with budesonide-surfactant than surfactant alone (RR 0.71; 95% CI, 0.59-0.86; I 2 = 68%).
  • In trials restricting treatment to within 4 h, BPD36 was reduced (RR 0.58; 95% CI, 0.46-0.72; eight trials; 1065 infants).
  • Trials permitting treatment after 4 h showed no BPD36 benefit (RR 0.98; 95% CI, 0.91-1.06; four trials; 2011 infants; P for subgroup difference < 0.00001).
  • Mortality and most other neonatal outcomes did not differ between groups; BPD or death showed a timing pattern similar to BPD36.

Why it matters

The pooled estimate suggests a possible reduction in BPD, but substantial heterogeneity and the contrasting timing subgroups make the overall result difficult to interpret. The apparent advantage of treatment within 4 h could reflect differences between trials rather than a true timing effect. Distinguishing these possibilities matters before this intervention is incorporated into routine neonatal care.

What to keep in mind

The timing analysis was post hoc and trial-level, so study differences and small-study effects may confound the apparent association. Heterogeneity in the overall analysis was substantial.

Source

Published in Eur J Pediatr. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Curative-intent management of de novo metastatic nasopharyngeal carcinoma: an evidence-based consensus guideline from the International Collaborating Oncology Organisations.

This international consensus guideline addresses curative-intent management of de novo metastatic nasopharyngeal carcinoma, a population historically treated with palliative intent.

Lancet OncolOct 29, 2026Read summary
Clinical ResearchHematology

Decitabine plus busulfan-cyclophosphamide versus busulfan-cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial.

This open-label, multicentre, randomised phase 3 trial compared decitabine plus busulfan-cyclophosphamide (DAC-BuCy) with BuCy conditioning before allogeneic HSCT in 130 patients aged 14–65 years with KMT2A-rearranged…

Lancet HaematolOct 30, 2026Read summary
Clinical ResearchPediatrics

Prone positioning and high-frequency oscillatory ventilation in early paediatric acute respiratory distress syndrome (PROSpect): an international, two-by-two factorial, response-adaptive, phase 3, randomised controlled trial.

PROSpect was an international, two-by-two factorial, phase 3 randomised controlled trial comparing prone with supine positioning and high-frequency oscillatory ventilation (HFOV) with conventional mechanical ventilation…

LancetOct 30, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.